We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+25.45%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$24.9M
Cap. Flow
-$80.8M
Cap. Flow %
-14.28%
Top 10 Hldgs %
51.19%
Holding
52
New
14
Increased
5
Reduced
20
Closed
7

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$35.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.9M
4
EW icon
Edwards Lifesciences
EW
+$15.4M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$13.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$35.9M
2
BBIO icon
BridgeBio Pharma
BBIO
+$32.3M
3
LLY icon
Eli Lilly
LLY
+$30.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$23.5M
5
NTRA icon
Natera
NTRA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$161B
$35.5M 6.28%
+289,312
New +$35.2M
BMY icon
2
Bristol-Myers Squibb
BMY
$127B
$34.9M 6.18%
+647,899
New +$31.2M
BSX icon
3
Boston Scientific
BSX
$65.8B
$34.4M 6.07%
360,428
+97,456
+37% +$9.55M
BBOT
4
BridgeBio Oncology
BBOT
$707M
$31.4M 5.55%
+410,700
New +$4.98M
LLY icon
5
Eli Lilly
LLY
$1.07T
$27.9M 4.92%
25,923
-31,453
-55% -$30.1M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.68B
$26.9M 4.76%
653,572
-14,043
-2% -$544K
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$25.4M 4.5%
119,265
-25,689
-18% -$5.31M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.84B
$25.1M 4.44%
1,196,807
-417,910
-26% -$7.29M
JNJ icon
9
Johnson & Johnson
JNJ
$635B
$25M 4.42%
+120,840
New +$23.9M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$68.8B
$23M 4.07%
29,797
-5,547
-16% -$3.77M
GPCR icon
11
Structure Therapeutics
GPCR
$3.49B
$17.6M 3.11%
252,901
-398,909
-61% -$16.3M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$16.7M 2.95%
360,340
-57,905
-14% -$3.17M
CYTK icon
13
Cytokinetics
CYTK
$11B
$16.4M 2.9%
258,381
-193,200
-43% -$12M
EW icon
14
Edwards Lifesciences
EW
$47.6B
$15.9M 2.82%
+187,048
New +$15.4M
ISRG icon
15
Intuitive Surgical
ISRG
$121B
$15.4M 2.72%
27,209
-44,134
-62% -$23.5M
NTRA icon
16
Natera
NTRA
$37.5B
$14.3M 2.52%
62,273
-86,096
-58% -$18M
ADPT icon
17
Adaptive Biotechnologies
ADPT
$3.56B
$13.3M 2.36%
821,195
-63,695
-7% -$1.04M
ABVX
18
Abivax
ABVX
$11B
$13.3M 2.35%
98,514
-63,627
-39% -$6.94M
SUPN icon
19
Supernus Pharmaceuticals
SUPN
$2.68B
$12.8M 2.26%
257,465
-29,625
-10% -$1.44M
GUTS icon
20
Fractyl Health
GUTS
$123M
$12.1M 2.14%
5,491,866
+277,630
+5% +$447K
MLYS icon
21
Mineralys Therapeutics
MLYS
$2.35B
$12M 2.13%
+331,849
New +$13.3M
PHAT icon
22
Phathom Pharmaceuticals
PHAT
$912M
$11.6M 2.05%
698,996
-429,525
-38% -$6.13M
ADMA icon
23
ADMA Biologics
ADMA
$1.92B
$10.3M 1.82%
564,461
-120,047
-18% -$2.02M
ACLX
24
DELISTED
Arcellx
ACLX
$10.2M 1.8%
+156,109
New +$12.5M
DYN icon
25
Dyne Therapeutics
DYN
$4.04B
$10.2M 1.8%
+519,715
New +$9.84M
1
2 3

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Catalio Capital Management held 52 positions worth $566M, up 4.6% from $541M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Catalio Capital Management withdrew a net $80.8M in Q4 2025, closing 7 positions and reducing 20 holdings. Its most notable exit was AbbVie, an estimated $35.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Gilead Sciences worth $35.5M.

  • Catalio Capital Management's largest Q4 2025 buy was Gilead Sciences: 289,312 shares worth $35.5M.
  • Catalio Capital Management added most to Boston Scientific in Q4 2025, an estimated $9.55M increase.
  • Catalio Capital Management's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $30.1M.
  • Catalio Capital Management fully exited AbbVie in Q4 2025, selling an estimated $35.9M.
  • Catalio Capital Management's ten largest holdings make up 51% of its $566M portfolio in Q4 2025.
  • Catalio Capital Management opened 14 new positions and closed 7 in Q4 2025.
  • Catalio Capital Management's portfolio value rose 4.6% quarter-over-quarter to $566M.

Based on Catalio Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.